Post by CTIN (Clinical Trials Information Network)

Glioblastoma in Spain: many trials, few patients. Yesterday we showed where Sjögren's patients are: a big pool, light competition, an easy market. Glioblastoma is the mirror image. In Spain: → Estimated patient pool: ~1,212 patients → Trials competing for them: 14 (4 actively recruiting) → Competition intensity: 11.6 trials per 1,000 patients For context, Sjögren's in Spain sits at 0.7 trials per 1,000. 𝗚𝗹𝗶𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮 𝗶𝘀 𝗻𝗲𝗮𝗿𝗹𝘆 𝟭𝟳× 𝗺𝗼𝗿𝗲 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 for roughly the same count of eligible patients. The pool is thin right across Europe, because the disease is rare (2.52 per million): → Germany: ~2,127 → France: ~1,714 → Italy: ~1,484 → Spain: ~1,212 → Poland: ~950 When estimated trial demand reaches 12.6% of an entire national pool, every site decision matters. Recruitment stops being a question of outreach volume. It becomes a question of who reaches the patients first. Same continent, same week, two rare diseases, opposite recruitment realities. One favours the sponsor. One favours whoever moves fastest. If you were running a glioblastoma trial, would you concentrate on the largest pools, or chase the lower-competition markets? 👇 🌍 We are CTIN → Clinical Trials Information Network 𝐖𝐞 𝐛𝐫𝐢𝐝𝐠𝐞 𝐄𝐮𝐫𝐨𝐩𝐞'𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝗲𝗺 🔍 Follow for clinical research market insights 🤝 Share to support our mission #ClinicalTrials #ClinicalResearch #Oncology